Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences
Y Roussel, D Raoult
New Microbes and New Infections, doi:10.1016/j.nmni.2020.100710
Funding and gifts from the pharmaceutical industry have an influence on the decisions made by physicians and medical experts. In the context of the coronavirus disease 2019 epidemic, several treatments are available to treat patients infected with the virus. Some are protected by patents, such as remdesivir, others0020stare not, such as hydroxychloroquine. We wanted to observe the possible correlation between the fact, for an academic doctor in infectious diseases, of having benefited from funding by Gilead Sciences, producer of remdesivir, and the public positions taken by this doctor towards hydroxychloroquine. Our results show a correlation (Spearman test, p = 0.017) between the amount received from the Gilead Sciences company and public opposition to the use of hydroxychloroquine in France. This should open up the debate on the role of the interest links of doctors with pharmaceutical companies in the medical and scientific public debate.
Conflicts of interest There is no conflict of interest.
References
Blumenthal, Doctors and drug companies, N Engl J Med
Cao, Wang, Wen, Liu, Wang et al., A Trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medRxiv,
doi:10.1101/2020.03.22.20040758Dana, Loewenstein, A social science perspective on gifts to physicians from industry, JAMA
De Novales, Ramírez-Olivencia, Estébanez, De Dios, Herrero et al., Early hydroxychloroquine is associated with an increase of survival in COVID-19 patients: an observational study, Preprints,
doi:10.20944/preprints202005.0057.v1Dejong, Aguilar, Tseng, Lin, Boscardin et al., Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries [published correction appears in, JAMA Intern Med
Edwards, Remdesivir shows promising results for coronavirus
Friedman, There's No such thing as a free lunch
Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study, Travel Med Infect Dis
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Gibbons, Landry, Blouch, Jones, Williams et al., A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts, J Gen Intern Med
Katz, Caplan, Merz, All gifts large and small: toward an understanding of the ethics of pharmaceutical industry gift-giving, Am J Bioeth
Lexchin, Interactions between physicians and the pharmaceutical industry: what does the literature say?, CMAJ
Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, medRxiv,
doi:10.1101/2020.04.16.20065920Mahevas, Tran, Roumier, Chabrol, Paule et al., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, medRxiv,
doi:10.1101/2020.04.10.20060699Million, Lagier, Gautret, Colson, Fournier et al., Full-length title: early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis,
doi:10.1016/j.tmaid.2020.101738Sharma, Vadhariya, Johnson, Marcum, Holmes, Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data, BMC Health Serv Res
Steinman, Shlipak, Mcphee, Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions, Am J Med
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial, medRxiv,
doi:10.1101/2020.04.10.20060558Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial, The Lancet,
doi:10.1016/S0140-6736(20)31022-9Watkins, Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study, BMJ
